TYK2
Non-receptor tyrosine-protein kinase TYK2
Protein Summary
Probably involved in intracellular signal transduction by being involved in the initiation of type I IFN signaling. Phosphorylates the interferon-alpha/beta receptor alpha chain. This gene encodes a member of the tyrosine kinase and, more specifically, the Janus kinases (JAKs) protein families. This protein associates with the cytoplasmic domain of type I and type II cytokine receptors and promulgate cytokine signals by phosphorylating receptor subunits. It is also component of both the type I and type III interferon signaling pathways. As such, it may play a role in anti-viral immunity. A mutation in this gene has been associated with hyperimmunoglobulin E syndrome (HIES) - a primary immunodeficiency characterized by elevated serum immunoglobulin E. [provided by RefSeq, Jul 2008]
- ENST00000264818
- ENSP00000264818
- ENSG00000105397
- ENST00000525621
- ENSP00000431885
- JTK1
- IMD35
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
protein domain | 1 | ||
molecular function | 0.98 | ||
histone modification site profile | 0.91 | ||
hub protein | 0.85 | ||
transcription factor | 0.76 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 461.71 (req: < 5)
Gene RIFs: 108 (req: <= 3)
Antibodies: 665 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 461.71 (req: >= 5)
Gene RIFs: 108 (req: > 3)
Antibodies: 665 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 12
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 417
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 8